Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Amgen
Seqker Biosciences, Inc.
AstraZeneca
Hangzhou Hanx Biopharmaceuticals, Ltd.
Idience Co., Ltd.
Stanford University
Arvinas Inc.
ImmunityBio, Inc.
Institut Claudius Regaud
National Cancer Center Hospital East
Gilead Sciences
Hackensack Meridian Health
Takeda
ANRS, Emerging Infectious Diseases
Bristol-Myers Squibb
Bristol-Myers Squibb
NRG Oncology
Tasly Pharmaceutical Group Co., Ltd
Hackensack Meridian Health
Lumos Pharma
Beth Israel Deaconess Medical Center
Artiva Biotherapeutics, Inc.
CRISPR Therapeutics
Hackensack Meridian Health
H. Lee Moffitt Cancer Center and Research Institute
BeOne Medicines
Nanjing Leads Biolabs Co.,Ltd
Fudan University
iOnctura
Canadian Cancer Trials Group
BriaCell Therapeutics Corporation
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Erasca, Inc.